Vaxart, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Vaxart, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $57.00K.
- Vaxart, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $0.00.
- Vaxart, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Vaxart, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- Vaxart, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $17.00K, a 92.38% decline from fiscal 2022.
- Vaxart, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $223.00K, a 87.22% decline from fiscal 2021.
- Vaxart, Inc. stock issued during period, value, stock options exercised for fiscal 2021 was $1.75M, a 189.87% increase from fiscal 2020.
- Vaxart, Inc. stock issued during period, value, stock options exercised for fiscal 2020 was $602.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $57.00K 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $0.00 derived: S-1 12 month − 10-Q 9 month · filed 2026-05-08 | $3.00K S-1 · filed 2026-05-08 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $3.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − S-1 3 month · filed 2026-08-06 | $12.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $3.00K S-1 · filed 2026-05-08 | $26.00K derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $0.00 derived: S-1 12 month − 10-Q 9 month · filed 2026-05-08 | $30.00K S-1 · filed 2026-05-08 |
| 2024-09-30 | $9.00K 10-Q · filed 2025-11-13 | $30.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $14.00K 10-Q · filed 2025-08-13 | $21.00K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $7.00K 10-Q · filed 2025-05-13 | $24.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $17.00K 10-K · filed 2025-03-20 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | |
| 2023-06-30 | $17.00K 10-Q · filed 2024-08-08 | |
| 2022-12-31 | $9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $223.00K 10-K · filed 2024-03-14 |
| 2022-09-30 | $135.00K 10-Q · filed 2023-11-02 | $719.00K derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $31.00K 10-Q · filed 2023-08-03 | $932.00K derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $48.00K 10-Q · filed 2023-05-04 | $1.56M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $505.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $1.75M 10-K · filed 2023-03-15 |
| 2021-09-30 | $348.00K 10-Q · filed 2022-11-09 | $1.44M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $661.00K 10-Q · filed 2022-08-08 | $1.38M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $231.00K 10-Q · filed 2022-05-09 | $815.00K derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $602.00K 10-K · filed 2022-02-24 |
| 2020-09-30 | $286.00K 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $98.00K 10-Q · filed 2021-08-05 | |
| 2020-03-31 | $18.00K 10-Q · filed 2021-05-06 | |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $13.00K 10-K · filed 2021-02-25 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-10 | |
| 2018-03-31 | $13.00K 10-Q · filed 2019-08-08 | |
| 2017-12-31 | $24.00K 10-K · filed 2019-02-06 | |
| 2011-12-31 | $627.00K 10-K · filed 2012-03-14 | |
| 2010-12-25 | $523.00K 10-K · filed 2012-03-14 | |
| 2009-12-26 | $431.00K 10-K · filed 2012-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |